


Expanding Manufacturing Capacity to Meet Demand

BD made strategic investments in 2008 to increase manufacturing capacity to help meet growing worldwide demand for its innovative technologies and products. Below are just a few examples of expansion projects BD undertook or completed this year. Each demonstrates the Company's commitment to providing customers with high-quality products that enhance the discovery and development of new medicines, the detection and diagnosis of infections and disease, and the safe and effective delivery of medicines.

Miami, Florida – Enabling discovery and development

BD announced plans to open a dedicated animal-free/antibiotic-free AF² Facility for the production of cell culture media and supplements by late 2009. This new \$53 million facility will serve the needs of pharmaceutical and biotechnology companies that require high-performance cell culture media products for the production of biological medicines, vaccines and stem cell therapies. With stringent raw materials controls and product segregation that are designed to eliminate the risk of contamination associated with cell culture media from facilities using animal-origin components, the AF² Facility will set a new standard for safety and quality.



New facilities in Canada, Florida and Hungary reflect BD's commitment to meet the need for innovative, high-quality products in the discovery and development, diagnosis and delivery phases of the healthcare continuum.

Québec, Canada – Improving detection and diagnosis

BD opened a new \$34 million manufacturing facility in Québec to help meet anticipated global demand for *BD GeneOhm* molecular assays. The *BD GeneOhm* MRSA Assay – now used in more than 400 hospitals in the U.S.,



Canada, Europe and Asia-Pacific – is the primary product manufactured in this facility. In addition, the Québec facility is currently producing *BD GeneOhm* assays for the detection of

methicillin-sensitive *Staphylococcus aureus*, vancomycin-resistant enterococci, *Clostridium difficile* and Group B streptococci.

Tatabánya, Hungary – Enhancing drug delivery

BD announced a €100 million capital investment project to build a state-of-the-art prefillable syringe manufacturing facility in Tatabánya, Hungary, which is expected to open in 2010. The new high-volume manufacturing facility will help BD meet

the growing worldwide demand for prefillable syringes that are sold to pharmaceutical companies. The prefilled syringe format has been found to reduce the potential for medication error and contamination.